Change of serum insulin-like growth factor-1 in primary nephrotic syndrome patients and its relationship with bone metabolism
10.3760/cma.j.issn.1001-7097.2010.08.006
- VernacularTitle:原发性肾病综合征患者血清胰岛素样生长因子1的变化及其与骨代谢的关系
- Author:
Ling WANG
;
Weijie YUAN
;
Lijie GU
;
Minghua SHANG
- Publication Type:Journal Article
- Keywords:
Nephrotie syndrome;
Bone metabolism;
Bone mineral density;
Insulin-like growth factor 1
- From:
Chinese Journal of Nephrology
2010;26(8):594-597
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the change of serum insulin-like growth factor 1(IGF-1)in primary nephrotic syndrome(PNS)patients and its relationship with bone metabolism, and to investigate the clinical significance of IGF-1 in the mechanism of bone metabolic disorders in PNS patients. Methods A total of 30 PNS patients with chronic kidney disease(CKD)stage 1 and 2 were randomly selected from 2008.1 to 2009.5 in our hospital. Serum IGF-1, albumin, calcium, phosphorus, PTH,25 hydroxy vitamin D3, bone gla protein(BGP), degradation products of C-terminal telopeptides of type I collagen(CTx), 24-hour urinary protein excretion, and ratio of urinary calcium to creatinine(UCa/Cr)were measured. Healthy control group of 61 persons were randomly selected from our medical examination center at the same time. Results Serum levels of calcium, 25 hydroxy vitamin D3 and BGP were significantly lower;CTx and UCa/Cr were significantly higher in PNS patients(P<0.05)as compared to healthy control group. BMD of PNS patients was lower but without significant difference compared with healthy control group[(1.078± 0.090)g/cm2 vs(1.090±0.062)g/cm2, P>0.05]. Serum level of IGF-1 was significantly lower in PNS patients and was positively correlated with BMD and BGP,and negatively correlated with 24-hour urinary protein excretion and CTx. Conclusions Bone metabolic disorder exists in PNS patients with the appearance of decreased bone formation and increased bone absorption.Serum level of IGF-1 has good correlations with bone biochemical markers.which may be used as a new bone biochemical marker of bone metabolism in kidney disease.
